The list of national projects SAS

Back to the list of institutes

Institute: Biomedical Research Center SAS

Life Science Alliance: Closing Research and Innovation Divide in the EU
Aliancia pre živé vedy: zmenšovanie výskumnej a inovačnej prepasti v Európskej únii
Program: Horizon 2020
Project leader: prof. RNDr. Pastoreková Silvia DrSc.
Duration: 1.1.2018 - 31.12.2019

Scientific capacity building in biomedical research through scientific exchange and co-development of research services
Budovanie vedeckých kapacít v biomedicínskom výskume prostredníctvom vedeckej výmeny a spoločného rozvoja výskumných služieb
Program: European Regional Development Fund (ERDF)
Project leader: Mgr. Nemčovičová Ivana PhD.
Annotation:The central aim of the project is to strengthen regional capacities and improve international reputation in the field of biomedical research. The joint development of state-of-the-art working processes and the emergence of a new protein acquisition platform for biomedical purposes are, among other things, to lay the foundations for the long-term cooperation of the participating institutions. Collaboration in the field of expertise between the Vienna Biocenter and the Biomedical Research Center of the Slovak Academy of Sciences will enable project CAPSID to develop new scientific services for the acquisition of proteins for biomedical research purposes. These highly specialized production and cleaning processes meet growing demand as well as increasing demand for high quality. Protein retrieval methods will be available through a new service platform. While implementing new methods, many students will be trained and the online platform will serve to exchange research outputs. Particular emphasis will be placed on international cooperation and intensive communication: conferences and workshops will be a meeting place for international scientists, experts from universities, research institutes and biotechnology companies that reside in a cross-border region.
Duration: 1.7.2018 - 31.12.2021

Targeted combination therapy of colon cancer with therapeutic gene/drug loaded novel dendritic nanocarriers
Cielená kombinovaná terapia nádoru hrubého čreva pomocou rozvetvených nanonosičov nesúcich terapeutický gén a liečivá
Program: Bilateral - other
Project leader: RNDr. Matúšková Miroslava PhD.
Annotation:Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths in the world, and prognosis remains dismal for patients with metastatic disease. Significant portion of early-stage patients develop recurrence after chemotherapy. There is a need for novel therapeutic approaches. Multifunctional nanocarriers enable targeted co-delivery of drugs and genes, while maintaining their chemo-physical properties and biological functions. Dendritic polymers possess controllable structure with a large population of terminal functional groups, low solution or melt viscosity, and good solubility. These properties allow their use in numerous bioapplications, including their application in targeted anti-tumour therapies. To increase the efficacy of conventional CRC treatment and to overcome drug resistance, we aim to develop multimodal nanotherapeutic system, for targeted delivery of multifunctional combinational therapy. Polyamidoamine - based dendrimers will be used to carry: cytotoxic drug 5-fluorouracil (5FU), plasmid containing apoptosis-mediating TRAIL gene, chemosensitising epigenetic agent suberoylanilide hydroxamic acid (SAHA), selective targeting moiety (folate molecules) and imaging agent. The safety and efficacy of the newly constructed dendritic molecules loaded with therapeutics will be evaluated. Nanocarriers will be synthesized and characterized by Genetic Engineering and Biotechnology Institute of TUBITAK Marmara Research Center. The biological effects will be assessed at Biomedical Research Center of Slovak Academy of Sciences. Therapeutic efficiency, potential toxicity, biodistribution, bioavailability, bioelimination, and release of therapeutics will be studied on CRC pre-clinical in vitro and in vivo models.
Duration: 3.9.2018 - 30.9.2021

Detection and Characterization of Rickettsiae and Similar Microorganisms.
Detekcia a charakterizácia Rickettsií a im podobných mikroorganizmov
Program: Bilateral - other
Project leader: RNDr. Sekeyová Zuzana PhD.
Annotation:Aims and results shared in this project will provide a number of theoretical knowledge in the field of molecular analysis of rickettsiae and a like microorganisms, with similar direct intrusions into medical practice, means such interferences that will predict and affect an analytical accuracy of diagnoses of rickettsioses, and similar, biologically active intracellular bacteria. We will provide a specific picture of the course of the diseases caused by them, and will try to transfer this knowledge to determination of the specific laboratory indicators of studied pathogens at the molecular level. Reliable diagnoses, vigilance, preparedness, and the availability of efficacious vaccines and antibiotics are dependent on assignation of precise biomarkers that will enhance diagnostic capabilities and reduce delayed identification or misdiagnosis of infectious agent.
Duration: 1.1.2018 - 31.12.2019

European Network of Bioadhesion Expertise: Fundamental Knowledge to Inspire Advanced Bonding Technologies
Drosophila salivary gland secretory proteins as tunable and biodegradable natural glue
Program: COST
Project leader: RNDr. Farkaš Robert CSc.
Duration: 1.1.2017 - 31.12.2020

In vitro 3-D total cell guidance and fitness
In vitro 3-D bunkové modely – metodické postupy a ich relevantnosť
Program: COST
Project leader: RNDr. Šramková Monika PhD.
Annotation:The present Action is aimed at refining our understanding of the in vivo microenvironment, reducing the differences when translating it in vitro, to create 3D total guidance ex vivo culture systems for the replacement of animal use. Traditional in vitro 2D culture systems fail to imitate the physiological and biochemical features of cells in the original tissue. Differences between the microenvironment provided by cell culture models and that distinct of the in vivo tissues are significant and can cause deviations in cell response and behaviour. In this COST Action, the present understanding of in vivo micro/macro-environment will be refined in order to reproduce in vitro the physiological system in the best possible way: surface topography, substrate stiffness, mechanical stimulation, chemical cues and localised density will be analysed. This will allow to develop reliable “3D total guidance” in vitro models reducing the number of animals used and allowing a safe translation of the present basic knowledge in cell repair and regeneration from the laboratory bench to the clinical application, with a positive impact on every day’s life patients and general Health costs.
Duration: 16.3.2017 - 15.3.2021

Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy
Inovatívne nanoliečivá: Nová kombinácia epigentických a protinádorových liečiv s génovou terapiou zacielená voči nádorovým kmeňovým bunkám karcinómu prsníka
Program: ERANET
Project leader: Mgr. Smolková Božena PhD.
Annotation:The aim of the INNOCENT project is to develop innovative multifunctional nanopharmaceuticals to overcome the low efficacy and frequent relapses in breast cancer (BC) treatment, with emphasis on cancer stem cells (CSCs). The proposed multimodal COMBOBOMB, brilliantly integrates the diagnostic and therapeutic functions within a single nanostructure. The COMBOBOMB harbours four major components: 1) a selective targeting moiety (chitosan-targeted CD44); 2) a diagnostic imaging aid for localization of the malignant tumour and its micro- or macrometastases (inorganic nanocrystals); 3) a cytotoxic drug (doxorubicin), and 4) a chemosensitising agent (decitabine, DAC along with DAC-activating enzyme) utilising gene therapy and epigenetic approaches.
Duration: 1.1.2017 - 31.12.2019

Inovatívne partnerstvo pre boj proti rakovine (Spoločná aktivita podporená Európskou komisiou v rámci tretieho programu v oblasti zdravia)
Program: Other
Project leader: prof. RNDr. Pastoreková Silvia DrSc.
Duration: 1.4.2018 - 31.3.2021

The Comet assay as a human biomonitoring tool
Kométový test ako nástroj na biologické monitorovanie ľudí
Program: COST
Project leader: RNDr. Gábelová Alena CSc.
Annotation:Many human biomonitoring studies have used the comet assay to measure DNA damage (some also measuring DNA repair). In most cases, the assay is applied to peripheral blood mononuclear cells. Results from relatively small individual studies are often inconsistent, and it is advantageous to carry out a pooled analysis of the combined data from all available studies. hCOMET will be a network comprising researchers who are active (or intend to be active) in human biomonitoring with this assay. Results supplied by these researchers will be compiled as a single database representing an estimated 19,000 individual DNA damage measurements. The pooled analysis will allow us to determine which factors (smoking, age, nutrition, sex, occupational exposure etc.) affect DNA damage, and to what extent. Fewer studies have included DNA repair capacity as an endpoint; we will collect what data we can and carry out a detailed review (or a pooled analysis if enough data). In addition, hCOMET will address the issue of inter-laboratory reproducibility of the assay by devising standard protocols, for both DNA damage and DNA repair measurement, coordinating ring studies to test these protocols, and offering training courses and exchanges, so that in future comparison of results from different studies will be facilitated. We will review applications of the assay to other human cell types and isolation methods (such as leukocytes obtained from frozen blood).
Duration: 1.4.2016 - 31.3.2020

High-field MRS, a tool to estimate the tissue-specific metabolic state reflecting thyroid hormone activity in vivo: validation of the “virtual biopsy” clinical relevance
Magnetická rezonančná spektroskopia ako nástroj na sledovanie tkanivovo-špecifického metabolických parametrov, ktoré sa spájajú s účinkami tyroidálnych hormónov in vivo: overenie klinickej relevantnosti takejto “vitruálnej biopsie”
Program: Bilateral - other
Project leader: Mgr. Ukropec Jozef DrSc.
Duration: 1.1.2018 - 31.12.2019

Skeletal muscle metabolic abnormalities in patients with idiopathic inflammatory myopathies
Metabolické abnormality kostrového svalu u pacientov s idiopatickými zápalovými myopatiami
Program: Bilateral - other
Project leader: doc. MUDr. Ukropcová Barbara PhD.
Duration: 1.4.2016 - 31.3.2020

Mitochondrial mapping: Evolution - Age - Gender - Lifestyle - Environment
MITO-EAGLE: Evolúcia-Vek-Pohlavie-Životný štýl-Prostredie
Program: COST
Project leader: Mgr. Ukropec Jozef DrSc.
Duration: 1.1.2017 - 1.9.2020

Molecular Markers for Biological Dosimetry in Radiation Oncology, Cancer Risk, Assesment and Optimizing Cancer Therapy
Molekulárne markery pre biologickú dozimetriu v radiačnej onkológii a hodnotenie rizika vzniku a optimalizácie liečby rakoviny
Program: IAEA
Project leader: doc. Ing. Beliaev Igor DrSc.
Annotation:Cytogenetic analysis remains the only standard method for biological dosimetry. It is generally accepted that new molecular markers associated with biological dosimetry and cancer risks should be established and dependence of these risks on conditions of irradiation such as dose should be verified. Relevant cellular model systems are needed to verify and predict these risks. Hematopoietic stem cells (HSC) are the major target of leukemogenesis and also most relevant cellular model for assessing cancer risk associated with ionizing radiation. Usually, characteristic chromosomal translocations resulting in so-called preleukemic fusion genes (PFG) arise prenatally in HSC as a first key event in multistage process of leukemogenesis. DNA double-strand breaks (DSB) are critical DNA damage resulting in PFG. CD34+ HSC stem cells from umbilical cord blood (UCB) will be studied in comparison to lymphocytes. The project will focus on the low dose range (≤10 cGy) to which people is usually exposed in aircrafts during flights, at security controls (airports) and during medical investigations (such as computer tomography and mammography). The data will be also obtained in higher dose range to find out whether the low dose effects can be extrapolated from the higher doses. This project will validate possible molecular markers for estimation of low-dose effects in HSC and lymphocytes which may be used in biodosimetry and cancer epidemiological studies. Possible correlation of constitutive and induced DNA damage and apoptosis will be analyzed in hematopoietic cells of ALL and AML patients. The obtained data will be correlated with immunophenotype, presence of PFG and clinical outcome such as treatment response, minimal residual disease (MRD), risk group, side effects. If some correlations will be established it may provide new strategy for optimizing cancer therapy.
Duration: 19.9.2017 - 9.7.2021

Cancer Nanomedicine - from the bench to the bedside
Nanomedicína rakoviny - z laboratória k pacientovi
Program: COST
Project leader: RNDr. Šramková Monika PhD.
Duration: 28.9.2018 - 27.9.2022

Neuroprotective potential of cryopreserved placental mesenchymal stem cells (MSCs), extract, cord blood serum in the spinal cord injury (SCI).
Neuroprotektívny potenciál zamrazených mezenchýmových kmeňových buniek (MSCs) placenty, extraktov, séra pupočníkovej krvi pri poranení miechy (SCI).
Program: Inter-academic agreement
Project leader: RNDr. Slovinská Lucia PhD.
Annotation:Determine the neuroprotective potential of cryopreserved placental MSC, placental extract and cord blood serum with spinal cord injuries. Determine the neuroprotective potential of cryopreserved placental MSC, placental extract and cord blood serum with spinal cord injuries.
Duration: 1.1.2017 - 31.12.2019

New diagnostic and therapeutic tools against multidrug resistant tumors
Nové diagnostické a terapeutické nástroje v liečbe mnoholiekovej rezistencie nádorov
Program: COST
Project leader: RNDr. Jurkovičová Dana PhD.
Duration: 11.9.2018 - 10.9.2022

Role of the CA IX ectodomain in tumor growth and metastasis
Úloha ektodomény CA IX v nádorovom raste a metastázovaní
Program: Other
Project leader: prof. RNDr. Pastoreková Silvia DrSc.
Annotation:This project is aimed at understanding the role of the CA IX ECD in tumor growth and metastasis in vivo using mouse models. We intend to evaluate growth of tumor xenografts (following subcutaneous implantation of tumor cells) and colonization of lungs (following injection of tumor cells into the tail vein) in absence and presence of the recombinant CA IX ECD. In addition, we plan to evaluate potential therapeutic targeting of CA IX ECD through analysis of the anticancer effect of antibodies binding to different regions of the ectodomain, including M75 and VII/20. Particularly M75 is of great interest, because the N-terminal PG region, to which M75 binds, was recently found to be involved in cell adhesion and spreading, the processes contributing to metastatic dissemination. On the other hand, MAb VII/20 binds to the central CA catalytic domain and was previously shown to reduce the growth of primary tumors, but its effect on metastasis has not been examined so far. Thus, we expect that the project will allow us to dissect the role of ECD in metastasis and propose antibody-based therapeutic strategies to reduce metastatic growth.
Duration: 11.11.2014 - 31.12.2019

Oxytocin role in the regulation of expression of GTPases in transgenic mouse model of neurodevelopmental disorder
Úloha oxytocínu v regulácii expresie GTPáz v transgénnom modeli neurovývinového ochorenia
Program: Bilateral - other
Project leader: RNDr. Bakoš Ján PhD.
Annotation:Neurodevelopmental diseases, particularly Prader-Willi syndrome, Schaaf-Yang syndrome and spectrum of autism disorders may be associated with deficiencies in oxytocin system. Oxytocin, a known reproductive hormone, is considered to be a trophic and differentiating factor in the brain, however, there is a lack of studies on the manipulation of oxytocin system in relation to brain development. French team created a Magel2-knockout mouse model and showed that the mutant pups suffer from lack of sucking initiation right after birth (in males and females) and show autistic behavior in male adulthood. This model is widely accepted as a model of human Prader-Willi syndrome, in which Magel2 is deleted, and Schaaf-Yang syndrome, presenting point mutations of Magel2. The major aim of the present collaborative project is to contribute to clarification of the oxytocin effects on expression of GTPases in transgenic mouse model of neurodevelopmental disorder. Slovak research team together with French partners will closely collaborate to analyze GTPases and evaluate cytoskeletal proteins associated with neurite growth under oxytocin influence in Magel2-deficient mice. Studying the role of oxytocin in the process of early brain maturation and to measure its potential to compensate the neurodevelopmental deficits can bring relevant data for clinical and regenerative medicine.
Duration: 1.1.2018 - 31.12.2019

Monitoring of effects of natural and synthetic ligands of nuclear retinoid receptors on key proteins involved in epithelial-mesenchymal transition in human breast cancer cells by the mass spectrometry
Využitie hmotnostnej spektrometrie pre sledovanie vplyvu prirodzených a syntetických ligandov nukleárnych retinoidných receptorov na kľúčové proteíny epiteliálne-mezenchymálneho prechodu u buniek karcinómu prsníka
Program: Inter-academic agreement
Project leader: Ing. Brtko Július DrSc.
Duration: 1.1.2018 - 31.12.2020

Developing of innovative method of spinal cord injury effective treatment.
Vývoj inovatívnej metódy na efektívnu liečbu poškodenia miechy.
Program: Inter-academic agreement
Project leader: RNDr. Gálik Ján CSc.
Duration: 1.1.2017 - 31.12.2019

The total number of projects: 20